HK Stock Market Move | CARSGEN-B(02171) rose over 3% in the afternoon; CT1190B completed the first patient infusion in its Phase I registrational clinical trial in China.
CARsgen Therapeutics-B (02171) rose over 3% in the afternoon. As of press time, it was up 3.04%, at HK$12.53, with a turnover of HK$20.6322 million.
CARSGEN-B(02171) rose over 3% in the afternoon, up 3.04% as of press time, at HK$12.53, with a turnover of HK$20.6322 million.
On the news front, on September 29, CARSGEN-B announced that CT1190B, a universal CAR-T cell product targeting CD19/CD20, has completed the first patient infusion in its Phase I registrational clinical trial in China, for the treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) who have failed at least two lines of standard therapy. The IIT study results of CT1190B were presented as a poster at the 2026 European Hematology Association (EHA) Annual Congress.
Related Articles
HK Stock Market Move | Copper stocks fluctuate higher; Deutsche Bank warns the copper market is facing a severe shortage, with gains potentially exceeding 50% in half a year.
Jefferies: Lowers BUD APAC (01876) target price to HK$7.5, third-quarter outlook faces challenges.
HK Stock Market Move | CHINA LESSO (02128) rises over 4%; overseas sales of plastic pipes achieved steady growth in the first half of the year; the company has now established production bases in multiple countries.
HK Stock Market Move | Copper stocks fluctuate higher; Deutsche Bank warns the copper market is facing a severe shortage, with gains potentially exceeding 50% in half a year.
Jefferies: Lowers BUD APAC (01876) target price to HK$7.5, third-quarter outlook faces challenges.
HK Stock Market Move | CHINA LESSO (02128) rises over 4%; overseas sales of plastic pipes achieved steady growth in the first half of the year; the company has now established production bases in multiple countries.
